Cargando…
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors
BACKGROUND: Although vaccines effectively prevent coronavirus disease 2019 (COVID-19) in healthy individuals, they appear to be less immunogenic in individuals with chronic inflammatory disease (CID) or receiving chronic immunosuppression therapy. METHODS: Here we assessed a cohort of 77 individuals...
Autores principales: | Chen, Rita E., Gorman, Matthew J., Zhu, Daniel Y., Carreño, Juan Manuel, Yuan, Dansu, VanBlargan, Laura A., Burdess, Samantha, Lauffenburger, Douglas A., Kim, Wooseob, Turner, Jackson S., Droit, Lindsay, Handley, Scott A., Chahin, Salim, Deepak, Parakkal, O’Halloran, Jane A., Paley, Michael A., Presti, Rachel M., Wu, Gregory F., Krammer, Florian, Alter, Galit, Ellebedy, Ali H., Kim, Alfred H.J., Diamond, Michael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599018/ https://www.ncbi.nlm.nih.gov/pubmed/34812429 http://dx.doi.org/10.1016/j.medj.2021.11.004 |
Ejemplares similares
-
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
por: Diamond, Michael, et al.
Publicado: (2021) -
Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021) -
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022) -
Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021) -
Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)